ES2213267T3 - Composicion para administracion por via nasal que contiene toxina vibrio colera zonula occludens como mejorador de absorcion. - Google Patents

Composicion para administracion por via nasal que contiene toxina vibrio colera zonula occludens como mejorador de absorcion.

Info

Publication number
ES2213267T3
ES2213267T3 ES98902381T ES98902381T ES2213267T3 ES 2213267 T3 ES2213267 T3 ES 2213267T3 ES 98902381 T ES98902381 T ES 98902381T ES 98902381 T ES98902381 T ES 98902381T ES 2213267 T3 ES2213267 T3 ES 2213267T3
Authority
ES
Spain
Prior art keywords
nasal
dosage composition
composition
zot
nasal dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98902381T
Other languages
English (en)
Spanish (es)
Inventor
Alessio Fasano
Teresa Demagistris
Sergio Uzzau
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
University of Maryland, College Park
Original Assignee
University of Maryland, Baltimore
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore, University of Maryland, College Park filed Critical University of Maryland, Baltimore
Application granted granted Critical
Publication of ES2213267T3 publication Critical patent/ES2213267T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES98902381T 1997-01-09 1998-01-09 Composicion para administracion por via nasal que contiene toxina vibrio colera zonula occludens como mejorador de absorcion. Expired - Lifetime ES2213267T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/781,057 US5908825A (en) 1997-01-09 1997-01-09 Dosage composition for nasal delivery and method of use of the same
US781057 1997-01-09

Publications (1)

Publication Number Publication Date
ES2213267T3 true ES2213267T3 (es) 2004-08-16

Family

ID=25121537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98902381T Expired - Lifetime ES2213267T3 (es) 1997-01-09 1998-01-09 Composicion para administracion por via nasal que contiene toxina vibrio colera zonula occludens como mejorador de absorcion.

Country Status (9)

Country Link
US (1) US5908825A (enExample)
EP (1) EP1028715B1 (enExample)
JP (2) JP2001524940A (enExample)
AT (1) ATE256460T1 (enExample)
AU (1) AU5906398A (enExample)
CA (1) CA2277824C (enExample)
DE (1) DE69820671T2 (enExample)
ES (1) ES2213267T3 (enExample)
WO (1) WO1998030211A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
AU712819B2 (en) * 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
ES2237551T3 (es) * 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
BR0214280A (pt) * 2001-11-19 2005-01-11 Becton Dickinson Co Composição farmacêuticas em forma particulada
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
CA2531491A1 (en) * 2003-07-15 2005-02-03 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
DE10351778A1 (de) 2003-11-06 2005-06-09 Daimlerchrysler Ag Verfahren zur Korrespondenzanalyse in Bilddatensätzen
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
AR060103A1 (es) 2006-02-09 2008-05-28 Alba Therapeutics Corp Formulaciones para un efector de uniones apretadas
AU2007233116B2 (en) * 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
WO2009023311A2 (en) * 2007-05-07 2009-02-19 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2009015382A2 (en) 2007-07-26 2009-01-29 Alba Therapeutics Corporation Novel peptides that enhance tight junction permeability
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
ES2628077T3 (es) 2009-02-27 2017-08-01 Pari GmbH Spezialisten für effektive Inhalation Dispositivo de inhalación de aerosol
BRPI1009644B1 (pt) 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
EP2380618A1 (en) * 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
EP3194422B1 (en) 2014-09-19 2020-04-29 Tensive Controls, Inc. Anti-microbial peptides
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021158463A1 (en) 2020-02-03 2021-08-12 Palatin Technologies, Inc. Diamine-linked receptor-specific cyclic peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470729A (en) * 1983-03-04 1995-11-28 University Of Maryland At Baltimore Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Also Published As

Publication number Publication date
EP1028715A1 (en) 2000-08-23
ATE256460T1 (de) 2004-01-15
DE69820671D1 (de) 2004-01-29
US5908825A (en) 1999-06-01
JP2001524940A (ja) 2001-12-04
EP1028715A4 (en) 2001-10-10
WO1998030211A1 (en) 1998-07-16
CA2277824C (en) 2006-11-07
AU5906398A (en) 1998-08-03
DE69820671T2 (de) 2004-09-30
JP2006028199A (ja) 2006-02-02
CA2277824A1 (en) 1998-07-16
EP1028715B1 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
EP1028715B1 (en) Dosage composition for nasal delivery comprising vibrio cholera zonula occludens toxin as absorption enhancer
ES2209133T3 (es) Zonulina sustancialmente pura, un modulador fisiologico de las uniones estrechas mamiferas.
ES2267282T3 (es) Antagonistas de peptido de zonulina y metodos para usarlos.
JP3846901B2 (ja) 腸送達用経口投与組成物およびその使用方法
JP3860208B2 (ja) 非毒性口内アジュバントとして有効な突然変異エンテロトキシン
PT732937E (pt) Adjuvante nao toxico das mucosas
JPWO2021235553A5 (enExample)
JPH04502610A (ja) ストレプトコッカルｍプロテイン由来の合成ペプタイド及び当該ペプタイドから調製されたワクチン
MXPA01001321A (en) Peptide antagonists of zonulin and methods for use of the same
HK1082210B (en) Peptide antagonists of zonulin and their use